TrovaGene Inc (TROV) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. TROV reported $-0.34 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.32. The company posted revenue of $.07 million in the period, compared to analysts expectations of $.20 million. TROV’s revenue was down -12.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Based on several research reports , TrovaGene Inc was Downgraded by Piper Jaffray to ” Underweight” on Mar 16, 2017. TrovaGene Inc was Downgraded by Maxim Group to ” Hold” on Mar 16, 2017.
Several company insiders have filed Insider transactions , on Dec 19, 2016, Stanley Tennant (director) purchased 10,000 shares at $2.10 per share price. According to the SEC, on Dec 19, 2016, William J Welch (CEO) purchased 4,750 shares at $2.09 per share price. On Dec 15, 2016, Mark Erlander (Chief Scientific Officer) purchased 5,000 shares at $2.08 per share price, according to the Form-4 filing with the securities and exchange commission.
TrovaGene Inc opened for trading at $1.7 and hit $1.75 on the upside on Wednesday, eventually ending the session at $1.75, with a gain of 6.06% or 0.1 points. The heightened volatility saw the trading volume jump to 2,05,417 shares. Company has a market cap of $54 M.
Trovagene Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Company’s primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology while its external focus includes entering into collaborations to develop its technology in areas such as infectious disease transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).